Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00546741 · ClinicalTrials.gov registry record · Phase 1
Drug Interaction With Metformin
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00546741 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 18 participants.
The verdict
NCT00546741, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the effect of metformin on dapagliflozin exposure and the effect of dapagliflozin on metformin exposure in healthy volunteers. Additionally, the safety and tolerability of dapagliflozin will be assessed in the presence and absence of metformin in healthy volunteers
Interventions
- DRUG Metformin
- DRUG Dapagliflozin
- DRUG Dapagliflozin + Metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00546741
The ClinicalTrials.gov registry entry for NCT00546741 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Metformin is the first listed.
NCT00546741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00546741 about?
NCT00546741 is a clinical study titled "Drug Interaction With Metformin". The purpose of the study is to determine the effect of metformin on dapagliflozin exposure and the effect of dapagliflozin on metformin exposure in healthy volunteers. Additionally, the safety and tolerability of dapagliflozin will be assessed in the presence and absence of metformin in healthy volu...
What is the current status of trial NCT00546741?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2007-11. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00546741?
The interventions under investigation include: Metformin (DRUG), Dapagliflozin (DRUG), Dapagliflozin + Metformin (DRUG).
Who is sponsoring clinical trial NCT00546741?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.